8-K: Corbus Pharmaceuticals Announces Promising Pre-Clinical Data for Obesity Drug CRB-913

Corbus Pharmaceuticals has released new pre-clinical data for CRB-913, a novel obesity treatment, showing significant weight loss and improved fat metabolism in mice.

Summary

• Corbus Pharmaceuticals presented pre-clinical data for CRB-913 at Obesity Week 2024, highlighting its potential as a treatment for obesity.
• CRB-913 is a second-generation CB1 receptor inverse agonist designed to be peripherally restricted, minimizing brain exposure.
• In mice, CRB-913 showed 15-fold lower brain levels compared to monlunabant at the same dose, indicating better peripheral restriction.
• The plasma-to-brain ratio for CRB-913 was 10 times higher than monlunabant and 50 times higher than rimonabant, further supporting its peripheral action.
• CRB-913 demonstrated a dose-dependent weight loss in diet-induced obese mice, achieving up to 38% weight loss after 28 days at 80 mg/kg/day.
• This dose range corresponds to human-equivalent doses of 30 mg/day to 450 mg/day.
• A study showed that weight loss induced by semaglutide could be maintained by switching to CRB-913, while weight was rapidly regained when switching to a vehicle.
• Switching from semaglutide to CRB-913 led to a doubling in fat percentage reduction compared to semaglutide alone, suggesting a unique effect on fat metabolism.
• Corbus plans to begin a Phase 1 clinical study for CRB-913 in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive pre-clinical data for CRB-913, with strong indications of efficacy and safety. The comparison to existing treatments is favorable, and the company is on track with its clinical development plans. The sentiment is very positive from an investment perspective.

Positives

• CRB-913 shows a high degree of peripheral restriction, potentially reducing central nervous system side effects.
• The drug demonstrates significant weight loss in pre-clinical models.
• CRB-913 can maintain weight loss after initial treatment with an incretin analog like semaglutide.
• The drug appears to have a unique effect on fat metabolism, leading to greater fat loss compared to semaglutide.
• The company is on track to begin a Phase 1 clinical study in early 2025.

Risks

• The data is pre-clinical and may not translate directly to human trials.
• The safety and efficacy of CRB-913 in humans are yet to be determined.
• Clinical trials may face unexpected delays or challenges.
• The competitive landscape for obesity treatments is intense, with many companies developing new therapies.

Future Outlook

The company anticipates starting a Phase 1 clinical trial for CRB-913 in the first quarter of 2025 and is exploring potential clinical uses as a monotherapy, combination therapy, and induction/maintenance therapy.

Management Comments

• Yuval Cohen, PhD, CEO of Corbus, stated that the new data adds noteworthy information to the pre-clinical characterization of CRB-913.
• The CEO also noted that the data provides important context in comparison to monlunabant.
• The CEO believes the data suggests potential clinical use both as a monotherapy as well as a maintenance therapy post incretin analog induction treatment.

Industry Context

The announcement comes amid a growing interest in novel obesity treatments, with many companies exploring different mechanisms of action. The focus on peripheral restriction for CB1 inverse agonists is a response to safety concerns with earlier drugs in this class that targeted the brain.

Comparison to Industry Standards

• The document compares CRB-913 to monlunabant and rimonabant, first-generation CB1 inverse agonists, highlighting its superior peripheral restriction.
• The weight loss results in mice are compared to those achieved with semaglutide, a widely used incretin analog, showing that CRB-913 can maintain and enhance weight loss.
• The document also references PADCEV, a Nectin-4 targeting ADC, and compares the safety profile of CRB-701, a next generation Nectin-4 targeting ADC, to it and other similar drugs such as Tivdak and 9MW-2821.
• The document also compares the safety and efficacy of CRB-701 to other cervical cancer treatments such as Tivdak and chemotherapy.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising pre-clinical data and potential for future revenue.
• Employees may benefit from the company's progress and potential growth.
• Patients may benefit from the development of new and effective obesity treatments.
• The company's success could lead to increased business for suppliers and partners.

Next Steps

• The company will complete IND-enabling studies for CRB-913.
• The company plans to initiate a Phase 1 clinical study for CRB-913 in the first quarter of 2025.
• The company will continue dose escalation and expansion studies for CRB-701.
• The company will continue to develop CRB-601 and expects first patient dosed in Q4-2024.

Key Dates

Keywords

CRB-913, obesity, CB1 receptor inverse agonist, weight loss, semaglutide, pre-clinical data, peripheral restriction, fat metabolism, clinical trial, monlunabant, rimonabant